Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Luitpold Pharmaceuticals |
---|---|
Information provided by: | Luitpold Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00087776 |
The primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with Taxoprexin Injection to those treated with Dacarbazine. In addition, the response rate to each drug, response duration, time to progression and time to treament failure will be measured. Toxicity will be evaluated and compared between the two groups.
Condition | Intervention |
---|---|
Malignant Melanoma |
Drug: Chemotherapy |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | P01-02-17 |
Study First Received: | July 13, 2004 |
Last Updated: | August 22, 2007 |
ClinicalTrials.gov Identifier: | NCT00087776 |
Health Authority: | United States: Food and Drug Administration |
Neuroectodermal Tumors Dacarbazine Nevus, Pigmented Neoplasms, Germ Cell and Embryonal |
Neuroepithelioma Nevus Neuroendocrine Tumors Melanoma |
Neoplasms Neoplasms by Histologic Type Neoplasms, Nerve Tissue Nevi and Melanomas |